Skip to main content

Advertisement

Cancer & Metabolism

New Content Item

2019 Article Collection: Breast Cancer and Metabolism

The biology of tumor cells in breast cancer is complex and relatively unexplored. Cancer & Metabolism is excited to present the following article highlights that identify novel biomarkers and metabolic profiles of different breast cancer subtypes.


- Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities

- Metabolomics of oncogene-specific metabolic reprogramming during breast cancer

- Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation

- Activation of pro-survival metabolic networks by 1,25(OH)2D3 does not hamper the sensitivity of breast cancer cells to chemotherapeutics

- The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer

New Content Item

Aims and scope

Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer including molecular biology and genetics. The journal is indexed in DOAJ, Emerging Sources Citation Index (ESCI), PubMed, and PubMed Central.

cancer progression

Featured article: Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Tronstad et al. investigated the role the role of succinate dehydrogenase in relation to Epithelial to mesenchymal transition (EMT) in breast cancer progression and therapy.

Editorial Board

Dr. Michael Pollak, co-Editor-in-Chief

Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.

"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."

New Content ItemDr. Matthew G. Vander Heiden, co-Editor-in-Chief

Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).

Editorial Board Members

Abass Alavi, University of Pennsylvania School of Medicine, USA 
Lewis Cantley, Weill Cornell Medical College, USA 
Peter Carmeliet, Vesalius Research Center, Belgium 
Ralph DeBerardinis, University of Texas Southwestern Medical Center, USA 
Teresa Fan, Markey Cancer Center, USA 
Robert Gatenby, H. Lee Moffitt Cancer Center and Research Institute, USA 
Kun-Liang Guan, University of  California, San Diego,
Rudolf Kaaks, German Cancer Research Center, Germany 
Andrew Lane, Markey Cancer Center, USA 
Gordon Mills, University of Texas M. D. Anderson Cancer Center, USA 
Lorenz Poellinger, Karolinska Institute, Sweden 
Jacques Pouyssegur, Institute of Research on Cancer and Aging, France 
Joshua Rabinowitz, Princeton University, USA
Peter Ratcliffe, Nuffield Department of Clinical Medicine, UK 


Jeffrey Rathmell, Duke University, USA 
Jared Rutter, University of Utah School of Medicine, USA 
David Sabatini, Whitehead Institute for Biomedical Research, USA 
Paolo Sassone-Corsi, University of California, Irvine, USA
Gregg Semenza, Johns Hopkins University School of Medicine, USA 
Celeste Simon, University of Pennsylvania School of Medicine, USA 
Alexei Vazquez, The Cancer Institute of New Jersey, USA 
Bert Vogelstein, Johns Hopkins University School of Medicine, USA 
Karen Vousden, Beatson Institute for Cancer Research, UK 
Kathryn Wellen, University of Pennsylvania, USA
Eileen White, The Cancer Institute of New Jersey, USA 
Yue Xiong, University of North Carolina, Chapel Hill, USA 

Chi Van Dang, Editor Emeritus

Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.

"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."

Articles

  5. Content type: Research

      |  

    Authors: Marina Rosso, Lara Lapyckyj, María José Besso, Marta Monge, Jaume Reventós, Francesc Canals, Jorge Oswaldo Quevedo Cuenca, María Laura Matos and Mónica Hebe Vazquez-Levin

Most recent articles RSS

View all articles

Efficient peer review

We recognize that scientifically sound, high-quality manuscripts often receive negative decisions from high-impact journals on the basis of perceived general interest levels or the absence of extensive mechanisms supporting research hypotheses. As a niche journal, Cancer & Metabolism will consider rapid publication of such manuscripts if they are submitted together with the original peer reviewer reports, letter of rejection, and a brief rebuttal.

Advertisement

Submit manuscript

Follow

Annual Journal Metrics

Advertisement

Cancer & Metabolism

ISSN: 2049-3002